Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W CLARKE

Showing results (811-820 of 856) with videos related to

Pageof 86
Sort By:
The Lancet. Oncology|July 6, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsClaire L Vale, David J Fisher, Peter J Godolphin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Plos Neglected Tropical Diseases|April 7, 2025
Bacillus cereus biovar anthracis causes inhalational anthrax-like disease in rabbits that is treatable with medical countermeasuresAllison M Ferris, David G Dawson, Andrea B Eyler, et al.
Lancet (London, England)|February 14, 2021
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E Langley, Duncan C Gilbert, Trinh Duong, et al.
Analytical and Bioanalytical Chemistry|August 25, 2021
Interlaboratory comparison of 25-hydroxyvitamin D assays: Vitamin D Standardization Program (VDSP) Intercomparison Study 2 - Part 1 liquid chromatography - tandem mass spectrometry (LC-MS/MS) assays - impact of 3-epi-25-hydroxyvitamin D<sub>3</sub> on assay performanceStephen A Wise, Johanna E Camara, Carolyn Q Burdette, et al.
European Urology|April 15, 2017
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic BiologySteven M Walker, Laura A Knight, Andrena M McCavigan, et al.
Pageof 86

Showing results (811-820 of 856) with videos related to

Sort By:
Pageof 86
The Lancet. Oncology|July 6, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsClaire L Vale, David J Fisher, Peter J Godolphin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Plos Neglected Tropical Diseases|April 7, 2025
Bacillus cereus biovar anthracis causes inhalational anthrax-like disease in rabbits that is treatable with medical countermeasuresAllison M Ferris, David G Dawson, Andrea B Eyler, et al.
Lancet (London, England)|February 14, 2021
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E Langley, Duncan C Gilbert, Trinh Duong, et al.
Analytical and Bioanalytical Chemistry|August 25, 2021
Interlaboratory comparison of 25-hydroxyvitamin D assays: Vitamin D Standardization Program (VDSP) Intercomparison Study 2 - Part 1 liquid chromatography - tandem mass spectrometry (LC-MS/MS) assays - impact of 3-epi-25-hydroxyvitamin D<sub>3</sub> on assay performanceStephen A Wise, Johanna E Camara, Carolyn Q Burdette, et al.
European Urology|April 15, 2017
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic BiologySteven M Walker, Laura A Knight, Andrena M McCavigan, et al.
Pageof 86